High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of colorectal cancer.
Metastatic Colorectal Cancer
BIOLOGICAL: High-activity natural killer
Relief degree of tumors, It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）, 3 months
Progress free survival（PFS）, 1 year|Overall survival（OS）, 3 years
By enrolling patients with small metastases of colorectal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).